The way the body reacts to powerful cancer treatments known as checkpoint inhibitors can differ significantly based on a patient’s skin color, potentially leading to delayed or inaccurate diagnoses of related toxicities. This emerging understanding, highlighted in a recent review of studies, underscores the critical demand for clinicians to consider dermatological presentations differently across diverse patient populations. Recognizing these variations is vital for ensuring equitable and effective cancer care.
Checkpoint inhibitors—a type of immunotherapy—have revolutionized cancer treatment over the past decade, offering novel hope for patients with melanoma, lung cancer, and other malignancies. However, these drugs work by unleashing the immune system, and sometimes that immune response can turn against the body’s own tissues, causing inflammation and a range of side effects. One common area affected is the skin, with reactions ranging from mild rashes to severe blistering.
The core of the concern lies in how these immune-related adverse events (irAEs) manifest and are interpreted on different skin tones. For example, vitiligo—a loss of skin pigment—can be a positive indicator that the immunotherapy is working, as it shows the immune system is active. But in patients with darker skin, vitiligo can be far more difficult to detect, potentially delaying recognition of treatment response or masking other, more concerning skin toxicities. Similarly, inflammation can present differently; what appears as subtle discoloration in lighter skin might be completely missed in darker skin, leading to underdiagnosis and delayed intervention.
The Challenge of Recognizing irAEs Across Skin Tones
The review, published in Medscape Medical News, points to a consistent pattern in the medical literature: dermatologic toxicities related to checkpoint inhibitors are often diagnosed later and are more severe in patients with skin of color. This isn’t because these patients are more susceptible to these side effects, but rather because of diagnostic delays stemming from a lack of awareness and training among healthcare providers regarding how these conditions present on diverse skin tones. A 2022 study published in the Journal of the American Academy of Dermatology found that dermatologists were less accurate in identifying inflammatory skin conditions in patients with Fitzpatrick skin types V and VI (darker skin tones) compared to those with lighter skin.
“Historically, medical education has relied heavily on images depicting conditions on lighter skin,” explains Dr. Nana Yaa Sarpong, a dermatologist specializing in skin of color at Massachusetts General Hospital, in a separate interview with time.news. “This creates a significant gap in knowledge when clinicians encounter the same conditions on patients with darker skin, where the visual cues are different.”
Specific Toxicities and Diagnostic Hurdles
Several specific irAEs pose particular challenges in patients with skin of color. Psoriasis-like eruptions, for instance, can appear as subtle scaling or hyperpigmentation rather than the classic raised, silvery plaques seen in lighter skin. Similarly, hand-foot syndrome—a common side effect causing redness, swelling, and pain on the palms and soles—may be mistaken for other conditions or simply dismissed as dry skin in individuals with darker complexions. Colitis, an inflammation of the colon, can also present atypically, with symptoms like abdominal pain and diarrhea being less readily attributed to the immunotherapy in patients whose baseline health conditions might be different.
The diagnostic process is further complicated by the fact that many skin conditions are already more prevalent or present differently in people of color. For example, keloids—raised scars—are more common in individuals with darker skin, and these can sometimes be confused with inflammatory skin reactions caused by checkpoint inhibitors. Similarly, conditions like hyperpigmentation and hypopigmentation are more common and can obscure the subtle changes indicative of irAEs.
The Role of Teledermatology and Increased Awareness
Efforts are underway to address these disparities. Teledermatology, where patients submit photos of their skin for remote evaluation by dermatologists, is emerging as a promising tool, particularly for patients in underserved areas with limited access to specialists. However, even with teledermatology, the quality of images and the clinician’s expertise in interpreting them on diverse skin tones remain crucial. The American Academy of Dermatology has launched initiatives to increase awareness of dermatologic conditions in skin of color and to improve training for dermatologists.
increased representation of diverse skin tones in medical textbooks and educational materials is essential. The development of standardized photographic scales that accurately depict irAEs across all Fitzpatrick skin types is also a priority. This includes creating atlases and training modules specifically designed to help clinicians recognize these conditions in diverse populations.
What This Means for Patients and Providers
For patients undergoing immunotherapy, it’s crucial to be proactive about reporting any new or changing skin symptoms to their healthcare team. Don’t assume that a rash or discoloration is simply a minor annoyance; it could be a sign of a serious irAE. For healthcare providers, the message is clear: broaden your diagnostic lens. Capture the time to carefully examine the skin of all patients, regardless of their skin tone, and consider the possibility of irAEs even when the presentation is atypical. A high index of suspicion and prompt referral to a dermatologist with expertise in skin of color can make all the difference.
The field of immunotherapy is rapidly evolving, and ongoing research is needed to better understand the nuances of irAEs in diverse populations. Future studies should focus on identifying biomarkers that can predict which patients are at higher risk of developing these toxicities and on developing targeted therapies to prevent or mitigate them. The goal is to ensure that all cancer patients, regardless of their skin color, have access to the most effective and equitable care possible.
The National Cancer Institute (NCI) continues to fund research into immunotherapy and its side effects. Updates on clinical trials and research findings can be found on the NCI website: https://www.cancer.gov/. The next major conference on immunotherapy, the Society for Immunotherapy of Cancer (SITC) Annual Meeting, is scheduled for November 2024, where new data on irAEs and strategies for managing them are expected to be presented.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Have you or a loved one experienced side effects from immunotherapy? Share your story in the comments below, and please share this article with anyone who might discover it helpful.
